GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Clarivate Identifies Eleven Potential Blockbuster and Transformative Drugs in 2025
Clarivate's 2025 Drugs to Watch report highlights 11 transformative therapies in obesity, oncology, gene therapy, and more, set to revolutionize patient care. These innovations, including AWIQLI®, CagriSema, and IMDELLTRA™, promise significant advancements in treatment paradigms and patient outcomes globally.
Multiple Sclerosis Treatment Market 2034: EMA, PDMA, FDA
The Multiple Sclerosis (MS) market is projected to grow significantly by 2034, with key players like Novartis, Biogen, and Hoffmann-La Roche leading in treatment development. MS, a chronic autoimmune disease affecting the CNS, lacks a cure but treatments aim to manage symptoms and slow progression. Emerging therapies and ongoing studies highlight advancements in MS care.
Essential Thrombocythemia Treatment Market 2034: EMA
The Essential Thrombocythemia (ET) market is set to grow significantly by 2034, driven by increasing disease prevalence and awareness. Key companies like Merck and PharmaEssentia are advancing treatments such as Bomedemstat and Ropeginterferon alfa-2b. ET, a rare blood disorder, is diagnosed through blood tests and genetic mutations, with treatments aiming to reduce thrombosis or bleeding risks.
GSK, Pfizer RSV Shots Required to Carry Guillain-Barré Syndrome Warnings
FDA mandates GSK and Pfizer to add Guillain-Barré syndrome risk warnings to their RSV vaccines, Arexvy and Abrysvo, following a study showing increased GBS cases post-vaccination. The risk, noted in the Warnings and Precautions section, applies within 42 days post-vaccination. This update, alongside CDC's narrowed RSV vaccine recommendations, may impact sales, with projections dropping to $1.7 billion by 2030.
Pfizer And GSK's RSV Vaccines Safety Labels Updated, FDA Adds Warning For Rare Neurological Disorder
FDA updates safety labels for Pfizer's Abrysvo and GSK's Arexvy RSV vaccines, warning of a potential increased risk of Guillain-Barré syndrome within 42 days post-vaccination. Study estimates nine excess GBS cases per million Abrysvo doses and seven per million Arexvy doses in individuals aged 65+. Further investigation needed to confirm causal link.
FDA adds warning to RSV shots from GSK, Pfizer
FDA requires GSK’s Arexvy and Pfizer’s Abrysvo RSV vaccines to carry warnings about a potential increased risk of Guillain-Barré syndrome (GBS), a rare neurological disorder. Despite this, the FDA affirms the vaccines' benefits outweigh risks, based on postmarketing data showing a low but increased GBS risk post-vaccination.
BIOSECURE, Merck Hansoh GLP-1 deal, Roche adds Innovent ADC, and Samsung venture
The BIOSECURE Act has impacted China's contract manufacturing, leading to asset sales by companies like WuXi AppTec and WuXi Biologics. Merck & Co. licensed a drug from Hansoh Pharma, and Roche partnered with Innovent Biologics for ADC development. Samsung Life Science Fund invested in Generate Biomedicines for AI-driven drug development.
FDA awards GSK breakthrough status for relapsed or refractory osteosarcoma treatment
GSK's GSK'227, a B7-H3-targeted antibody-drug conjugate, received FDA breakthrough therapy designation for treating relapsed or refractory osteosarcoma. Supported by Phase II ARTEMIS-002 trial data, it addresses an urgent unmet need in patients with limited treatment options. GSK acquired global rights to GSK'227, aiming for further clinical development and commercialization.
Clarivate Identifies Eleven Potential Blockbuster and Transformative Drugs in Annual Drugs to Watch Report
Clarivate's 2025 Drugs to Watch report highlights 11 transformative therapies in obesity, oncology, gene therapy, and more, set to achieve blockbuster status or revolutionize treatment by 2030. Innovations include AI in drug discovery, next-gen GLP-1 therapies for obesity, and gene editing for personalized medicine, aiming to improve global patient care.
© Copyright 2025. All Rights Reserved by MedPath